{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:14:33Z","timestamp":1789823673058,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.annder.2010.09.003","type":"journal-article","created":{"date-parts":[[2010,10,17]],"date-time":"2010-10-17T04:13:53Z","timestamp":1287288833000},"page":"746-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acn\u00e9 et contraception hormonale"],"prefix":"10.1016","volume":"137","author":[{"given":"M.","family":"Faure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Drapier-Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2010.09.003_bib0005","first-page":"142","article-title":"Les traitements hormonaux de l\u2019acn\u00e9","volume":"130","author":"Faure","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2010.09.003_bib0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0151-9638(06)70900-0","article-title":"Nouvelles contraceptions","volume":"133","author":"Faure","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2010.09.003_bib0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.maturitas.2004.01.001","article-title":"Pharmacological profile of progestins","volume":"47","author":"Sitruk-Ware","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.annder.2010.09.003_bib0020","doi-asserted-by":"crossref","first-page":"104S","DOI":"10.1016\/S0002-9343(99)80067-9","article-title":"The androgenicity of progestins","volume":"98","author":"Darney","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2010.09.003_bib0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/00003495-200363050-00003","article-title":"Progestogens with antiandrogenic properties","volume":"63","author":"Raudrant","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.annder.2010.09.003_bib0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1020072325818","article-title":"Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception","volume":"3","author":"Stanczyk","year":"2002","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.annder.2010.09.003_bib0035","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0022-4731(75)90311-8","article-title":"Use of cyproterone acetate in the treatment of acne, hirsutism and virilism","volume":"6","author":"Hammerstein","year":"1975","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.annder.2010.09.003_bib0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0303-7207(02)00377-5","article-title":"Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line","volume":"198","author":"Terouane","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.annder.2010.09.003_bib0045","doi-asserted-by":"crossref","first-page":"30512","DOI":"10.1016\/S0010-7824(02)00536-X","article-title":"A 12-month evaluation of the CMA-containing oral contraceptive Belara\u00ae: efficacy, tolerability and anti-androgenic properties","volume":"67","author":"Schramm","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.annder.2010.09.003_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000051701","article-title":"Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE\/CMA (Belara\u00ae) and EE\/LNG (Microgynon\u00ae)","volume":"203","author":"Worret","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2010.09.003_bib0055","first-page":"S69","article-title":"Antiandrogenic properties of the dienogest-containing oral contraceptive Valette\u00ae","volume":"35","author":"Moore","year":"1999","journal-title":"Drugs Today"},{"key":"10.1016\/j.annder.2010.09.003_bib0060","first-page":"S97","article-title":"Effects of the dienogest-containing oral contraceptive Valette\u00ae on skin and hair. Results of a postmarketing surveillance study","volume":"35","author":"Zimmermann","year":"1999","journal-title":"Drugs Today"},{"issue":"Suppl 4","key":"10.1016\/j.annder.2010.09.003_bib0065","first-page":"2","article-title":"The effect of 2\u00a0combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"van Vloten","year":"2002","journal-title":"Cutis"},{"key":"10.1016\/j.annder.2010.09.003_bib0070","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1080\/14730782.2000.12288987","article-title":"The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects","volume":"5","author":"Foidart","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.annder.2010.09.003_bib0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/09513590701214414","article-title":"Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line","volume":"23","author":"Paris","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.annder.2010.09.003_bib0080","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0190-9622(97)70112-9","article-title":"Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris","volume":"37","author":"Lucky","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2010.09.003_bib0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0029-7844(97)00059-8","article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial","volume":"89","author":"Redmond","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.annder.2010.09.003_bib0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2007.11.003","article-title":"Efficacy and safety of 3mg drospirenone\/20\u00a0mcg ethinylestradiol oral contraceptive administered in 24\/4\u00a0regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial","volume":"77","author":"Koltun","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.annder.2010.09.003_bib0095","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.contraception.2008.10.010","article-title":"Efficacy of a combined oral contraceptive containing 0,030mg ethinylestradiol\/2mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0,035mg ethinylestradiol\/2mg cyproterone acetate","volume":"79","author":"Palombo-Kinne","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.annder.2010.09.003_bib0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.contraception.2009.02.016","article-title":"Efficacy of an oral contraceptive containing EE 0,03mg and CMA 2mg (Belara\u00ae) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial","volume":"80","author":"Plewig","year":"2009","journal-title":"Contraception"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963810003789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963810003789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:56:32Z","timestamp":1758970592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963810003789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0151963810003789"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2010.09.003","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acn\u00e9 et contraception hormonale","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2010.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved","name":"copyright","label":"Copyright"}]}}